TNF and hepatosplenic T-cell lymphoma: In addition, a relationship between anti-TNF use for the treatment of irritable bowel disease and the development of hepatosplenic T-cell lymphoma (HSTCL) (96), has been suggested by a literature review study that found 11% (22/200) of HSTCL cases reported in the literature were associated with IBD treatment (97).